Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00139074

Purpose

The primary purpose is to investigate whether the addition of sodium valproate will be superior to treatment with quetiapine (Seroquel) given as monotherapy for an additional 14 days in non-responding patients after a 14 day initial treatment period with quetiapine.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Condition	Intervention	Phase
Bipolar Disorder	Drug: Quetiapine fumarate Drug: sodium valproate	Phase IV

MedlinePlus related topics: Bipolar Disorder

Drug Information available for: Divalproex sodium Valproate Sodium Valproic acid Quetiapine Quetiapine fumarate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Phase IV Study to Investigate if Valproate Add-on Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

The number of responders in the two treatment groups (quetiapine + sodium valproate placebo/quetiapine + sodium valproate) [ Time Frame: after 2 weeks treatment ] [ Designated as safety issue: No ]

Estimated Enrollment:	300
Study Start Date:	July 2005
Estimated Study Completion Date:	August 2010

Arms	Assigned Interventions
1: Active Comparator quetiapine fumarate monotherapy	Drug: Quetiapine fumarate oral variable dose
2: Experimental Quetiapine + sodium valproate	Drug: Quetiapine fumarate oral variable dose Drug: sodium valproate oral

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients suffering from a manic or mixed episode.

Exclusion Criteria:

Patients who have not provided personal informed consent,
Known intolerance, hypersensitivity or lack of antimanic response to sodium valproate or quetiapine fumarate,
Involuntary admittance/detainment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00139074

Locations

Denmark
Research Site
Esbjerg, Denmark
Research Site
Frederikssund, Denmark
Research Site
Haderslev, Denmark
Researcg Site
Svendborg, Denmark
Research Site
Kolding, Denmark
Research Site
Kobenhavn, Denmark
Research Site
Hellerup, Denmark

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:	Dr. Rasmus Wenzer Licht	AstraZeneca
Study Director:	AstraZeneca Seroquel Medical Science Director, MD	AstraZeneca

More Information

Study ID Numbers:	D1449L00010
Study First Received:	August 29, 2005
Last Updated:	December 19, 2008
ClinicalTrials.gov Identifier:	NCT00139074
Health Authority:	Denmark: Danish Medicines Agency

Keywords provided by AstraZeneca:

Bipolar I Disorder (DSM-IV 296.01, DSM-IV 296.4, DSM-IV 296.61)

Study placed in the following topic categories:

Quetiapine
Affective Disorders, Psychotic
Mental Disorders
Bipolar Disorder

Mood Disorders
Psychotic Disorders
Valproic Acid

Additional relevant MeSH terms:

Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Depressants
Enzyme Inhibitors

Antipsychotic Agents
Antimanic Agents
Pharmacologic Actions
Therapeutic Uses
GABA Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on January 16, 2009